Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem‐cell transplantation is a prognostic marker of longer progression‐free survival and overall survival-Reference-Cited by-同舟云学术

Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem‐cell transplantation is a prognostic marker of longer progression‐free survival and overall survival

Published:2022-04-05 Issue:2 Volume:198 Page:278-287
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Dávila Julio¹^ORCID,González‐Calle Verónica²,Escalante Fernando³,Cerdá Seila⁴,Puig Noemí²,García‐Sanz Ramón²^ORCID,Bárez Abelardo¹,Montes Carmen⁵,López Rosa⁶,Alonso José María⁷,Aguilar Carlos⁸,García‐Mateo Aránzazu⁹,Labrador Jorge¹⁰,Aguilera Carmen¹¹,García‐Coca Alfonso¹²,Hernández Roberto¹³,Mateos María‐Victoria²^ORCID,Ocio Enrique M.⁵^ORCID

Affiliation:

1. Department of Hematology Complejo Asistencial de Avila Spain

2. Department of Hematology University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research‐IBMCC (USAL‐CSIC) Salamanca Spain

3. Department of Hematology Complejo Asistencial Universitario de León León Spain

4. Department of Hematology Hospital de Laredo Laredo Spain

5. Department of Hematology Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria Santander Spain

6. Department of Hematology Hospital Virgen del Puerto Plasencia Spain

7. Department of Hematology Complejo Asistencial Universitario de Palencia Palencia Spain

8. Department of Hematology Complejo Asistencial de Soria Soria Spain

9. Department of Hematology Complejo Asistencial de Segovia Segovia Spain

10. Department of Hematology Complejo Asistencial Universitario de Burgos Burgos Spain

11. Department of Hematology Hospital El Bierzo, Ponferrada Spain

12. Department of Hematology Hospital Clínico Universitario de Valladolid Valladolid Spain

13. Department of Hematology Complejo Asistencial de Zamora Zamora Spain

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18182

Reference39 articles.

1. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

2. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline

3. NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020

4. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

5. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a nomogram prognostic model for early Grade ≥ 3 infection in newly diagnosed multiple myeloma based on immunoparesis;International Immunopharmacology;2024-01

2. Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial;British Journal of Haematology;2023-09-10

3. Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future;Cancers;2023-07-20

4. Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice;International Journal of Hematology;2023-01-24

5. Multiple myeloma treatment – should be continued or not?;British Journal of Haematology;2022-04-25